ClinicalTrials.gg
Active, not recruitingNCT04454658Updated Jul 16, 2025

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

A Phase 1 interventional study of ABBV-744 and Navitoclax in Myelofibrosis (MF), sponsored by AbbVie. Active, not recruiting at 43 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Enrollment
269th of 388
21 · median 40
Started
2020
with 14 others
Phase 1
117 of 454
26 open now
Primary completion
2027-01
later than 36 of 104 live
Registered
355th of 454
by date

Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 269th largest by enrollment of the 388 interventional ones that give a count, is one of 15 that started in 2020, is one of 117 in phase 1, reaches primary completion later than 36 of the 104 other live ones, and was the 355th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how safe and tolerable ABBV-744 is, when given alone, and in combination with ruxolitinib or navitoclax, for adult participants with MF.

ABBV-744 is an investigational drug being developed for the treatment of MF. The study has 4 segments - A, B, C, and D. In Segment A, the safe dosing regimen of ABBV-744 is identified and then, given alone as monotherapy. In Segment B, C, and D, combination therapies of ABBV-744 with either ruxolitinib or navitoclax are given. Adult participants with a diagnosis of MF will be enrolled. Around 130 participants will be enrolled in 60 sites worldwide.

In Segment A, participants will receive different doses and schedules of oral ABBV-744 tablet to identify safe dosing regimen. Additional participants will be enrolled at the identified monotherapy dosign regimen. In Segment B, participants will receive oral ruxolitinib and ABBV-744 will be given as "add-on" therapy. In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will receive treatment until disease progression or the participants are not able to tolerate the study drugs.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.

03

Conditions studied

  • Myelofibrosis (MF)

Keywords

  • ABBV-744
  • Navitoclax
  • Ruxolitinib
  • ABT-263
  • Cancer
  • Myelofibrosis
  • MF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Laboratory values indicative of adequate bone marrow, renal, and hepatic function meeting protocol criteria.
  • Completion of the Myelofibrosis System Assessment Form (MFSAF) on at least 4 out of the 7 days prior to Day 1 with at least 2 symptoms with a score >=3 or a total score of >=10.
  • Documented diagnosis of intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocytopenia MF (PET-MF) as defined by the World Health Organization (WHO).
  • (ECOG) Performance Status of \<= 2.
  • Intermediate - 2, or High-Risk disease as defined by the Dynamic International Prognostic Scoring System (For Segment A only, Intermediate - 1 with palpable splenomegaly >=5 centimeters [cm] below costal margin are also eligible).
  • Splenomegaly defined as spleen palpation measurement >= 5 cm below costal margin or spleen volume >= 450 cubic cms as assessed by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan (for Segments A and C, baseline spleen assessment must be obtained > 7 days after discontinuation of most recent Myelofibrosis (MF) therapy. If possible, this assessment should occur within 10 days of Cycle 1 Day 1).

Segment-Specific Prior Therapy Criteria:

  • Segment A:

    • Prior exposure to one or more Janus Kinase inhibitors (JAKi),[the most recent of which was discontinued > 14 days prior to Cycle 1 Day 1] and are intolerant, resistant, or lost response to the JAKi.
  • Segment B:

    • Currently receiving ruxolitinib AND
    • Willingness to reduce ruxolitinib dose (if on a higher dose); and on a stable dose for 14 days or longer prior to Cycle 1 Day 1; AND
    • At least one of the following criteria (a, b, or c):

      1. >= 24 weeks duration of current ruxolitinib course, with evidence of disease that is resistant, refractory, or has lost response to ruxolitinib therapy;
      2. \< 24 weeks duration of current ruxolitinib course with documented resistance, refractories, or loss of response, as defined by any of the following:

        • Appearance of new splenomegaly that is palpable to at least 5 cm below the left costal margin (LCM), in participants with no evidence of splenomegaly prior to the initiation of ruxolitinib.
        • >=100% increase in the palpable distance below the LCM, in participants with measurable spleen distance 5 - 10 cm prior to the initiation of ruxolitinib.
        • >=50% increase in the palpable distance below the LCM, in participants with measurable spleen > 10 cm prior to the initiation of ruxolitinib.
        • A spleen volume increase >= 25% (as assessed by MRI or CT) in participants with a spleen volume assessment available prior to the initiation of ruxolitinib.
      3. Prior treatment with ruxolitinib for >= 28 days complicated by any of the following:

        • Development of red blood cell transfusion requirement (at least 2 units/month for 2 months).
        • Grade >= 3 adverse events of neutropenia and/or anemia while on ruxolitinib treatment, with improvement or resolution upon dose reduction.
  • Segment C:

    • Prior exposure to one or more JAKi (the most recent of which was discontinued > 14 days prior to Cycle 1 Day 1), and are intolerant, resistant, refractory or lost response to the JAKi.

Exclusion criteria

Exclusion Criteria:

Segment-Specific Prior Therapy Criteria:

  • Segment A:

    • Prior exposure to one or more Bromodomain and Extra-Terminal (BET) inhibitors.
  • Segment B:

    • Prior exposure to one or more BET inhibitors.
  • Segment C:

    • Prior exposure to one or more BET inhibitors and/or any B-Cell Lymphoma 2 (BCL)-2 and/or BCL- XL inhibitor, including navitoclax.
  • Segment D:

    • Prior exposure to JAKi and/or any BET inhibitor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Segment A: ABBV-744 Dose Identification and Optimization

    Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.

    Drug: ABBV-744

  • Experimental
    Segment A: ABBV-744 Monotherapy

    Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.

    Drug: ABBV-744

  • Experimental
    Segment B: Ruxolitinib + ABBV-744 "Add on" Therapy

    Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as "add-on" therapy.

    Drug: ABBV-744 · Drug: Ruxolitinib

  • Experimental
    Segment C: ABBV-744 + Navitoclax

    Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.

    Drug: ABBV-744 · Drug: Navitoclax

  • Experimental
    Segment D: ABBV-744 + Ruxolitinib

    Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.

    Drug: ABBV-744 · Drug: Ruxolitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Up to Approximately 1 year from start of study

Secondary outcomes

  1. Percentage Of Participants Who Achieve Spleen Volume Reduction Of 35% Or Greater (SVR35)

    Reduction in spleen volume is measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.

    Time frame: Up To Week 24

  2. Maximum Observed Plasma Concentration (Cmax) of ABBV-744

    Maximum observed plasma concentration (Cmax) of ABBV-744.

    Time frame: Up To Week 12

  3. Time To Cmax (Tmax) Of ABBV-744

    The amount of time taken to reach Cmax.

    Time frame: Up To Week 12

  4. Area Under The Concentration Versus Time Curve (AUC) Of ABBV-744

    AUC of ABBV-744 will be calculated.

    Time frame: Up To Week 12

  5. Half-Life (t1/2) Of ABBV-744

    Half-life of ABBV-744 will be calculated.

    Time frame: Up To Week 12

  6. Accumulation Ratio Of ABBV-744

    Pharmacokinetic parameters will include accumulation ratio of ABBV-744.

    Time frame: Up To Week 12

  7. Apparent Clearance (CL/F) Of ABBV-744

    CL/F of ABBV-744 will be calculated.

    Time frame: Up To Week 12

  8. Apparent Volume Of Distribution (Vd/F) Of ABBV-744

    Vd/F of ABBV-744 will be calculated.

    Time frame: Up To Week 12

  9. Percentage Of Participants With >= 50% Reduction In Total Symptom Score (TSS)

    TSS is assessed using the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0. MFSAF v4.0 measures the burden of myelofibrosis-related symptoms. The symptoms are assessed on a 11-point numeric rating scale (NRS) anchored from 0 (absent) to 10 (worst imaginable).

    Time frame: Up to Week 24

  10. Objective Response Rate (ORR)

    ORR is defined as the sum of rates of partial remission (PR) or better.

    Time frame: Week 24

  11. Maximum Observed Plasma Concentration (Cmax) Of Navitoclax

    Maximum Observed Plasma Concentration (Cmax) Of Navitoclax.

    Time frame: Up To Week 12

  12. Time To Cmax (Tmax) Of Navitoclax

    The amount of time taken to reach Cmax.

    Time frame: Up To Week 12

  13. Area Under The Concentration Versus Time Curve (AUC) Of Navitoclax

    AUC of Navitoclax will be calculated.

    Time frame: Up To Week 12

  14. Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib

    Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib.

    Time frame: Up To Week 12

  15. Time To Cmax (Tmax) Of Ruxolitinib

    The amount of time taken to reach Cmax.

    Time frame: Up To Week 12

  16. Area Under The Concentration Versus Time Curve (AUC) Of Ruxolitinib

    AUC of Ruxolitinib will be calculated.

    Time frame: Up To Week 12

07

Study locations

43 sites
08

References and documents

Publications

  • Mascarenhas J, Fogliatto L, Green S, Corvalan I, Traer E, Kirito K, Chuah H, Sakatoku K, Hoeg R, Khawandanah M, Lavie D, Hunter Z, Quinn D, Wang Y, Harb J, Zha J, Malyankar U, Ritchie E. Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis. Blood Adv. 2026 May 26;10(10):3543-3553. doi: 10.1182/bloodadvances.2025018695. PubMed 41843794 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jan 2027, 74 months after the start.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 1, 2020
StartActual
Nov 11, 2020
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04454658
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 1, 2020
Start date
Nov 11, 2020
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jul 16, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion